MedPath

Shandong New Time Pharmaceutical Co., Ltd.

Shandong New Time Pharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

26

Active:0
Completed:4

Trial Phases

5 Phases

Phase 1:7
Phase 2:11
Phase 3:4
+2 more phases

Drug Approvals

4

FDA:4

Drug Approvals

Sevoflurane

Approval Date
Jan 12, 2024
FDA

Milrinone Lactate

Approval Date
Jan 10, 2024
FDA

Rosuvastatin Calcium

Approval Date
Jan 10, 2024
FDA

Isosorbide Mononitrate

Approval Date
Dec 22, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials

Phase 2
11 (42.3%)
Phase 1
7 (26.9%)
Phase 3
4 (15.4%)
Not Applicable
2 (7.7%)
Phase 4
2 (7.7%)

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

Not Applicable
Not yet recruiting
Conditions
Type 2 Diabetes (T2DM)
Interventions
Drug: F027
First Posted Date
2025-07-01
Last Posted Date
2025-07-01
Lead Sponsor
Shandong New Time Pharmaceutical Co., LTD
Target Recruit Count
496
Registration Number
NCT07046273

A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents

Phase 3
Conditions
Essential Hypertension
Interventions
Drug: Valsartan Oral Solution
Drug: Placebo
First Posted Date
2025-03-07
Last Posted Date
2025-03-07
Lead Sponsor
Shandong New Time Pharmaceutical Co., LTD
Target Recruit Count
342
Registration Number
NCT06863987
Locations
🇨🇳

Shandong New Time Pharmaceutical Co.LTD,, Linyi, Shandong, China

Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria

Phase 3
Recruiting
Conditions
Acute Urticaria
Interventions
Drug: Cetirizine Hydrochloride Injection
Drug: Diphenhydramine Hydrochloride Injection
First Posted Date
2025-02-11
Last Posted Date
2025-02-11
Lead Sponsor
Shandong New Time Pharmaceutical Co., LTD
Target Recruit Count
284
Registration Number
NCT06819774
Locations
🇨🇳

Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, BeiJing, Beijing, China

Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding

Phase 2
Not yet recruiting
Conditions
Peptic Ulcer Bleeding
Interventions
Drug: Vonorasan fumarate injection1
Drug: Vonorasan fumarate injection2
First Posted Date
2025-01-20
Last Posted Date
2025-01-20
Lead Sponsor
Shandong New Time Pharmaceutical Co., LTD
Target Recruit Count
150
Registration Number
NCT06783257

A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction

Phase 2
Recruiting
Conditions
Postoperative Gastrointestinal Dysfunction
Interventions
Drug: Mosapride Citrate Injection(low)
Drug: Mosapride Citrate Injection(high)
Drug: Placebo
First Posted Date
2025-01-20
Last Posted Date
2025-01-20
Lead Sponsor
Shandong New Time Pharmaceutical Co., LTD
Target Recruit Count
150
Registration Number
NCT06782594
Locations
🇨🇳

Shandong New Time Pharmaceutical Co., LTD, Feixian, Shandong, China

🇨🇳

Tongji Hospital Affiliated to Tongji Medical College Hust, Wuhan, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.